Targeted inhibitor of mutated KRAS gene shows promise in lung, bowel, other solid tumors
A novel agent that targets a mutated form of the KRAS gene—the most commonly altered oncogene in human cancers and one long considered "undruggable"—shrank tumors in most patients in a clinical trial with manageable side ...
Oct 25, 2020
0
17